Formula: C 14 H 24 CuN 6 O 4 Molecular Weight (MW): 403.9 g/mol Dose: 100 mg Purity: 98% (HPLC) Storage: 20C, protect from light Documentation: COA + HPLC + Mass Spec Research Use Declaration This material is supplied exclusively for in-vitro and pre-clinical laboratory research purposes
For oral administration, clinical trials have studied doses ranging from 1-30 mg daily, with typical protocols using 1-2 mg per dose on an empty stomach
These values reflect reported experimental parameters only and are provided strictly for research use, never for human application
Cardiometabolic Risk Reduction Clinical Trials: Cagrilintide is currently in Phase 3 clinical development
This ensures 100% bioavailability, quickly restoring your baseline energy, mental clarity, and metabolic function
Avoid freezing : Ice crystal formation can damage peptide structure